Glaucoma

CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.

Deborah Ristvedt, DO, and Melissa Tawa, OD, FAAO, detail the benefits of interventional glaucoma during their CRU 2025 presentation.

Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.

Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.

The new service will work to reduce waiting times for glaucoma assessments, monitoring, and treatment.

If executed, the reverse merger would create a new ophthalmic company that pairs two FDA-approved technologies for use in glaucoma patients.

The retrospective cohort study included adults with POAG from 12 tertiary-care health systems participating in the SOURCE Ophthalmology Big Data consortium in the US.

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.

The Preservative Freedom Coalition’s recent Glaucoma Patient Experience survey also found a need to better communication between patients and eye care providers.

The study, published in JAMA Network Open, found that only 8.2% of patients who were referred and received a glaucoma evaluation were diagnosed with glaucoma.

Researchers set out to determine the age groups for which a polygenic risk score would most effectively predict glaucomatous risk and help inform cost-effective methods for disease detection.

Key parameters captured by the module include disc area, cup area, cup volume, minimal cup depth, maximum cup depth, cup/disc area ratio, rim absence angle, and disc-damage likelihood scale.

NCX 470 0.1% achieved an intraocular pressure of less than or equal to 18 mmHg compared to latanoprost 0.005% in the trial.

Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

LL-BMT1 is a sustained drug delivery approach via a 3D-printed, drug-eluting contact lens to be used in glaucoma care that successfully completed a Phase 2b clinical trial.

Attention to patients' near visual needs is warranted when choosing medications.

The CREST Registry study reported on the safety and effectiveness outcomes of microinvasive cyclodialysis clef formation with the CycloPen system, followed by scleral reinforcement with AlloFlo Bio-Tissue implantation, according to Iantrek.

All QLS-111 concentrations and dose regimens in both Osprey and Apteryx trials “demonstrated excellent safety and tolerability,” according to the company.

C.Rex is the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.

The 12-year nationwide cohort found that significant differences in open angle glaucoma risk when assessing the presence of aura were not recorded between the study groups.

Preservatives may disrupt the ocular surface, contributing to poor adherence.

The guideline, titled "Care of the Patient with Primary Open-Angle Glaucoma," was developed by the AOA Evidence-based Optometry Guideline Development Group.